Bluejay Diagnostics closes $3.5M public offering of common stock and warrants

Bluejay Diagnostics, Inc.

2,692,308 units sold at $1.30/unit: one share (or pre-funded warrant) plus one warrant to buy one share.
Gross proceeds ~$3.5M; net proceeds to fund FDA approval, clinical studies, R&D, and working capital.
Warrants exercisable at $1.30/share for 5 years; pre-funded warrants exercisable at $0.0001.
H.C. Wainwright as placement agent; 7% cash fee and 188,462 placement agent warrants at $1.625.
Offering closed Jan 2, 2024; registered on Form S-1 effective Dec 27, 2023.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Bluejay Diagnostics, Inc. entered into Purchase Agreement with certain institutional investors (effective 2023-12-27).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Effective: 2023-12-27

Exact text from the filing

On December 27, 2023, Bluejay Diagnostics, Inc. (the “Company”) commenced a public offering (such transaction, the “Offering”) for the issuance and sale of (i) 537,768 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and (ii) prefunded warrants to purchase up to an aggregate 2,154,540 shares of Common Stock (the “Prefunded Warrants”). The Shares and Prefunded Warrants were sold together with warrants to purchase up to an aggregate of 2,692,308 shares of Common Stock at an exercise price of $1.30 per share (the “Warrants”). Certain institutional investors purchasing securities as part of the offering entered into a securities purchase agreement with the Company (the “Purchase Agreement”), dated as of December 27, 2023.

View on SEC.gov

269 material agreements filed in the last 30 days. Browse all material agreements →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-000317

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.